Cargando…

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition

BACKGROUND: Cyclin-dependent kinase 7 (CDK7) is crucial for cell cycle progression and gene expression transcriptional regulation, which are often not assessed in cancer developing process. CDK7 inhibitors have emerged as promising drugs for treating diverse cancers, including breast cancer. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Jingyu, Yang, Ming, Bi, Ran, Wang, Yueyuan, Wang, Chunxi, Wei, Xue, Zhang, Zhihao, Xie, Xiao, Wei, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183379/ https://www.ncbi.nlm.nih.gov/pubmed/34109118 http://dx.doi.org/10.3389/fonc.2021.664848

Ejemplares similares

The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer
por: Zhou, Yueyuan, et al.
Publicado: (2022)

p53–GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival
por: Wang, Yueyuan, et al.
Publicado: (2021)

Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1
por: Wang, Yueyuan, et al.
Publicado: (2022)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner
por: Zhou, Xinyu, et al.
Publicado: (2022)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer
por: Ionkina, Anastasia A., et al.
Publicado: (2017)

Knockdown of SPON2 inhibits the growth of triple-negative breast cancer
por: Hu, Xueyi, et al.
Publicado: (2023)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

WFDC21P promotes triple-negative breast cancer proliferation and migration through WFDC21P/miR-628/SMAD3 axis
por: Wei, Yu-Bo, et al.
Publicado: (2022)

CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism
por: Abudureheman, Tuersunayi, et al.
Publicado: (2021)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

NOL6 Regulates the Proliferation and Apoptosis of Gastric Cancer Cells via Regulating TP53I3, CDK4 and MCM7 Expression
por: He, Lei, et al.
Publicado: (2022)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Resveratrol Mediates the Apoptosis of Triple Negative Breast Cancer Cells by Reducing POLD1 Expression
por: Liang, Zhi-Jie, et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis
por: Hao, Kai-jun, et al.
Publicado: (2022)

Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report
por: Chen, Dongmei, et al.
Publicado: (2022)

RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
por: Si, Wentao, et al.
Publicado: (2022)

CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
por: Li, Xiao, et al.
Publicado: (2022)

Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer
por: Cui, Nai-Peng, et al.
Publicado: (2021)

Transcriptome Analysis Reveals MFGE8-HAPLN3 Fusion as a Novel Biomarker in Triple-Negative Breast Cancer
por: Wang, Meng-Yuan, et al.
Publicado: (2021)

CDK7 is a prognostic biomarker for non-small cell lung cancer
por: Kuempers, Christiane, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer
por: Li, Huihui, et al.
Publicado: (2023)

DJ-1 promotes osteosarcoma progression through activating CDK4/RB/E2F1 signaling pathway
por: Han, Zhitao, et al.
Publicado: (2022)

Andrographolide Enhances TRAIL-Induced Apoptosis via p53-Mediated Death Receptors Up-Regulation and Suppression of the NF-кB Pathway in Bladder Cancer Cells
por: Deng, Yuyou, et al.
Publicado: (2019)

Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway
por: Wang, Kai-nan, et al.
Publicado: (2022)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ts5fnueav4j01nk9kigbrvg1nh